Companies › Epygenix
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Clemizole HCl (EPX-100) | – | Phase 3 | Dravet Syndrome; Lennox Gastaut Syndrome; Healthy Participants | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07879170 | Clemizole HCl (EPX-100) | Phase 1 | Healthy Participants | Other | Dec 2026 |
| NCT04462770 | Clemizole HCl (EPX-100) | Phase 3 | Dravet Syndrome | Neurology | Apr 2027 |
| NCT05066217 | Clemizole HCl (EPX-100) | Phase 3 | Lennox Gastaut Syndrome | Neurology | Nov 2029 |
No annotated target.
–
GRIN Therapeutics Bracco Diagnostics NeuroDerm Cartesian Therapeutics Laboratorios Silanes S.A. de C.V.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.